Trials / Unknown
UnknownNCT05130684
Neo-NTP-CRT for Locally Advanced ESCC
Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- National Taiwan University Hospital · Academic / Other
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The investigators hypothesize that nivolumab combined with neoadjuvant chemoradiotherapy (CRT) is safe and effective in patients with locally advanced esophageal squamous cell carcinoma (LAESCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | adding nivolumab to conventional neoadjuvant CRT |
Timeline
- Start date
- 2021-02-22
- Primary completion
- 2023-03-01
- Completion
- 2024-03-01
- First posted
- 2021-11-23
- Last updated
- 2021-11-23
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT05130684. Inclusion in this directory is not an endorsement.